PolyActiva
Melbourne, Australia· Est.
Biodegradable ocular implants delivering sustained drug dosing for glaucoma and retinal disorders.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Biodegradable ocular implants delivering sustained drug dosing for glaucoma and retinal disorders.
Ophthalmology
Technology Platform
PREZIA™ is a polymeric pro‑drug system that covalently links drug molecules to a biodegradable polymer, enabling precise, controlled, and sustained intra‑ocular drug release over weeks to months.
Opportunities
Leveraging PREZIA™ to replace daily eye drops and frequent injections could capture a large share of the glaucoma market and open pathways into rare retinal disease therapies.
Risk Factors
Technical challenges in consistent drug release, regulatory approval for novel implantable devices, and competition from existing sustained‑release ocular platforms.
Competitive Landscape
Key competitors include Allergan (Bausch + Lombard) and Novartis (Durysta) for sustained‑release glaucoma solutions; PolyActiva differentiates through a biodegradable polymeric pro‑drug platform offering flexible dosing durations and formulation types.